This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Beijing Institute of Biological Products Co., Ltd
Beijing Institute of Biological Products Co., Ltd., commonly referred to as BIBP, is a leading player in the biopharmaceutical industry, headquartered in Beijing, China. Established in 1993, the company has made significant strides in the development and production of vaccines and biological products, serving both domestic and international markets. BIBP is renowned for its innovative vaccine solutions, including those for infectious diseases, which are pivotal in public health initiatives. The company’s commitment to research and development has positioned it as a key contributor to the global biopharmaceutical landscape. With a robust portfolio of products and a focus on quality and safety, BIBP continues to achieve notable milestones, solidifying its reputation as a trusted name in the industry.
DitchCarbon Score
How does Beijing Institute of Biological Products Co., Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Beijing Institute of Biological Products Co., Ltd's score of 25 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Beijing Institute of Biological Products Co., Ltd, headquartered in China, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of China National Pharmaceutical Group Corporation, which may influence its climate strategies and commitments. As of now, there are no documented reduction targets or climate pledges from Beijing Institute of Biological Products Co., Ltd. This lack of specific initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy or reporting framework. Given the context of the pharmaceutical industry, which is increasingly focusing on sustainability and carbon footprint reduction, it is likely that Beijing Institute of Biological Products Co., Ltd will need to align with broader industry standards and expectations regarding climate commitments in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 30,741,540 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 88,611,470 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Beijing Institute of Biological Products Co., Ltd is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
